Literature DB >> 34918326

Antiviral Treatments for Influenza.

Emanuele Palomba1,2,3, Valeria Castelli1,2,3, Giulia Renisi1, Alessandra Bandera1,2,3, Andrea Lombardi1,2, Andrea Gori1,2,3.   

Abstract

Influenza is an acute respiratory illness caused by the influenza A, B, and C viruses. It can occur in local outbreaks or seasonal epidemics, with possibility to spread worldwide in a pandemic when a novel strain with significant antigenic differences emerges. During the past years, several new drugs have become available, with different accessibility related to specific countries' approval. We have conducted a review of literature, analyzing the most recent data on efficacy and safety of drugs currently available to treat influenza, with a particular attention toward special populations. Efficacy and safety profile of neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and recently approved cap-dependent endonuclease inhibitor baloxavir marboxil are reported in literature, but still little information is available about special populations such as critically ill patients and patients with a history of chronic respiratory disease. Moreover, the emergence of strains with reduced or no susceptibility to current drugs is a matter of concern, suggesting the need of constant monitoring of viral variants. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34918326     DOI: 10.1055/s-0041-1733830

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  1 in total

1.  Antiviral Effects of ABMA and DABMA against Influenza Virus In Vitro and In Vivo via Regulating the Endolysosomal Pathway and Autophagy.

Authors:  Hongtao Liu; Chunlai Jiang; Yu Wu; Min Wu; Jiaxin Wu; Guanshu Zhao; Jie Sun; Xinyu Huang; Jiemin Li; Rui Sheng; Julien Barbier; Jean-Christophe Cintrat; Daniel Gillet; Weiheng Su
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.